Study: Diabetes drug eases HIV treatment effects
研究显示：糖尿病药物可以减轻艾滋病治疗的副作用

☆ diabetes 糖尿病

Monday, May 24, 2004 Posted: 5:44 PM EDT (2144 GMT)

欢迎就本文到论坛发表评论
http://bbs.wwenglish.org/dispbbs.asp?boardid=108&id=104158

WASHINGTON (Reuters) -- A diabetes drug could help reduce some of the health-threatening side effects of AIDS medications, U.S. researchers said.
华盛顿(路透社)----美国研究者称，一种用来治疗糖尿病的药物，可以减轻艾滋病治疗过程中，对健康的损害。

☆ medication 药物治疗

They said Avandia can help reduce the odd redistribution of body fat seen when patients take certain cocktails of AIDS drugs and also reduces some of the diabetes-like changes in metabolism.
他们称，Avandia(以上所提到的治疗糖尿病药物)能减轻鸡尾酒疗法所引起体内脂肪的重新分布，以及其他类似糖尿病的代谢异常。

☆ cocktails of AIDS 艾滋病的鸡尾酒疗法

Writing in the Annals of Internal Medicine, a team at Massachusetts General Hospital and Harvard Medical School in Boston said Monday they found that daily doses of GlaxoSmithKline's Avandia, known generically as rosiglitazone, helped patients better handle naturally occurring insulin.
该报道发表于内科学年报上，麻省医院及波士顿哈佛医学院的研究小组称，他们于周一发现，使用常规剂量的GlaxoSmithKline的Avandia，即众所周知的rosiglitazone，可以帮助患者自主产生胰岛素。

☆ insulin 胰岛素

The AIDS cocktails, known as highly active antiretroviral therapy or HAART, can keep patients with the deadly virus alive and healthy. But they have severe side effects including changes in how fat is distributed on the body.
艾滋病鸡尾酒疗法，即高活性抗反录病毒疗法或HAART，可以维持病毒携带者的生命及健康。但是该疗法也存在很严重的副作用，包括改变体内脂肪的正常分布。

Some AIDS patients simply lose body fat, while others see odd build-ups of fat on the shoulders or, more dangerously, around the internal organs. Many HIV patients lose fat in their faces, giving them a gaunt look, while gaining it elsewhere.
一些艾滋病患者表现为体内脂肪的丢失，而其他则表现为体内脂肪暂时性重分配，如肩部，严重者可分布到内脏周围。很多患者脸上脂肪减少，看起来很瘦，但在其他部位则出现大量脂肪堆积。

"The metabolic complications of this condition are becoming more significant as patients spend more time on HAART," Dr. Colleen Hadigan, who led the study, said in a statement.

"For example, we now know that 14 percent of men on this therapy may develop type-2 diabetes, which is four times the usual risk; and concerns are also increasing about the related risk of heart disease."

Her team studied 27 patients who randomly got either Avandia or a placebo for three months.

The Avandia patients had a 20 percent improvement in insulin sensitivity, a measure of a patient's risk of diabetes.

"We were able to demonstrate that this class of agents can slow down or reverse fat loss in patients with fat atrophy," Hadigan added. "However there are still a lot of questions to be answered about safety before these results can be widely applied."